Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 510 across all filing types
Latest filing 2018-06-04 Director's Dealing
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Otrzymanie zawiadomienia od osoby pełniącej obowiązki zarządcze - Content (PL)
Director's Dealing Classification · 1% confidence The document text is very short (426 characters) and explicitly states that a notification ('zawiadomienie') regarding a transaction by a person discharging managerial responsibilities (PDMR) under MAR Regulation Article 19 has been received, and the full content of the notification is attached ('Pełną treści zawiadomienia załączono do niniejszego raportu.'). This structure—a brief announcement stating an attachment contains the details—fits the definition of a Report Publication Announcement (RPA) or potentially a Regulatory Filing (RNS) if RPA is too specific. However, the content specifically relates to insider trading (Director's Dealing under MAR Article 19). Since there is no specific code for MAR Article 19 filings, we must check the provided definitions. The closest thematic match is 'Director's Dealing' (DIRS), which covers personal share transactions by directors. Given the 'MENU VS MEAL' rule, this is an announcement *about* the filing, not the filing itself. However, DIRS is defined as the 'Report of personal share transactions by company directors and executives (insider trades)'. If the attached document *is* the MAR 19 notification, then DIRS is the most appropriate content classification. Since the document itself is just the cover letter announcing the attached MAR 19 notification, RPA or RNS is technically correct based on the length rule. Given that MAR 19 notifications are a very specific type of insider transaction report, classifying it as DIRS (Director's Dealing) is the most informative choice, assuming the attached document is the actual DIRS report, even if this specific text is the announcement wrapper. I will prioritize the content type (Insider Dealing) over the wrapper format (RPA/RNS) because DIRS is a specific content category provided, and the text clearly describes an insider transaction report.
2018-06-04 Polish
Zawiadomienie o nabyciu akcji przez Szymona Rutę
Director's Dealing Classification · 1% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction/transactions referred to in Article 19(1) of the MAR Regulation). It details a transaction (Nabycie/Acquisition) of shares by a member of the Management Board (Szymon Ruta) of Scope Fluidics S.A. Article 19 of the MAR Regulation mandates reporting of transactions conducted by persons discharging managerial responsibilities (PDMRs). This specific type of insider transaction reporting aligns directly with the definition of Director's Dealing (DIRS).
2018-06-04 Polish
Otrzymanie zawiadomienia od osoby pełniącej obowiązki zarządcze - Content (PL)
Director's Dealing Classification · 1% confidence The document text is very short (420 characters) and explicitly states that a notification ('zawiadomienie') regarding a transaction by a person discharging managerial responsibilities (PDMR), specifically Mr. Szymon Ruta (Member of the Management Board), was received under MAR Regulation Article 19. It concludes by stating that the full content of the notification is attached ('Pełną treści zawiadomienia załączono do niniejszego raportu.'). This structure—a brief announcement referencing an attached document detailing insider transactions—fits the definition of a Director's Dealing report (DIRS) being announced, but based on the 'MENU VS MEAL' rule, since this is an announcement that the actual detailed filing (the MAR 19 notification) is attached, it is best classified as a general Regulatory Filing (RNS) or potentially a Report Publication Announcement (RPA). Given that MAR 19 notifications are specific insider trade reports, DIRS is the most accurate content classification, but the format suggests an announcement. Since DIRS is a specific category for director transactions, and this document *is* the announcement of that transaction filing, I will prioritize the content type (Director's Dealing) over the announcement format, as DIRS often encompasses these MAR 19 filings. However, reviewing the definitions, DIRS is 'Report of personal share transactions by company directors and executives (insider trades)'. The text *is* the report of the transaction notification received. I will classify it as DIRS as it directly concerns insider dealing notification under MAR 19.
2018-06-04 Polish
Zakończenie etapu prac nad projektem Bacteromic - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a formal announcement from the Management Board ('Zarząd') of Scope Fluidics S.A. detailing the completion of the second stage of research and development (R&D) work on the Bacteromic system, including the development of prototypes, manufacturing procedures, and patent applications. This content describes significant operational and developmental progress, which is typically disclosed as material information. Since it is a detailed update on internal progress rather than a standard financial report (10-K, IR, ER) or a simple announcement of a report's publication (RPA), it best fits the category for general regulatory announcements or significant operational updates. Given the options, 'Regulatory Filings' (RNS) serves as the most appropriate general category for material, non-standardized operational disclosures that aren't explicitly covered by other codes like MANG, CAP, or LTR. The document length is short (1626 chars), but it contains substantive information, not just a notice to download a report.
2018-04-03 Polish
Podpisanie listu intencyjnego z ALAB laboratoria - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is in Polish and describes a Letter of Intent (list intencyjny) signed between Scope Fluidics S.A. and ALAB laboratoria to validate and industrialize key projects, specifically the PCR|ONE system. This concerns a strategic partnership and validation process for a core technology, which falls under business development or strategic agreements. Since there is no specific category for 'Letter of Intent' or 'Strategic Partnership Announcement,' and the content is a substantive announcement about a business development activity rather than a routine regulatory update (like DIRS, DIV, or DVA) or a financial report (like 10-K, IR, ER), the most appropriate fallback category is 'Regulatory Filings' (RNS), as it is a significant, non-standard corporate announcement. Reviewing the definitions: - It is not an AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS. - It is not a pure Earnings Release (ER) or Interim Report (IR). - It is a strategic business development announcement. Given the options, RNS (Regulatory Filings / miscellaneous announcements) is the best fit for a significant, non-standard corporate action announcement that doesn't fit elsewhere.
2018-01-16 Polish
Zakończenie etapu prac nad projektem PCR|ONE - Content (PL)
Management Reports Classification · 1% confidence The document is a formal announcement from the Management Board ('Zarząd') of Scope Fluidics S.A. detailing the completion of the second stage of R&D work on the PCR|ONE system, referencing a prior Information Document. It summarizes progress on industrialization discussions, production line design, certification analysis, and future research recommendations. This content describes ongoing operational and strategic progress, which aligns best with a Management Report (MDA) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure not covered elsewhere. Given the detailed summary of R&D milestones, industrialization plans, and strategic next steps, it functions as a management update on business progress, fitting the description of Management Reports (MDA) better than a general regulatory filing (RNS). It is not a financial report (ER, IR, 10-K), a presentation (IP), or a simple announcement of a report (RPA).
2018-01-09 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.